CRL:NYSECharles River Laboratories International, Inc. Analysis
Data as of 2026-03-27 - not real-time
$165.13
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Charles River Laboratories trades around $165, roughly 55% above its DCF‑derived fair value of $107, indicating a material pricing premium. The stock shows a neutral technical stance – price sits just below the 20‑day SMA, RSI is mid‑range at 48, and a bullish MACD histogram suggests short‑term upside, yet volume is decreasing and the 30‑day volatility is high at over 50%.
Fundamentally, the company posted flat revenue (-0.8% YoY) with a negative profit margin (-3.6%) and a negative ROE, while its forward earnings estimate (+$12.19 EPS) and a forward PE of 13.5 are well below the industry average of 25.5, hinting at a value tilt. Recent guidance cuts tied to $200 M of divestitures and a neutral analyst rating add downside pressure, but strategic collaborations and a strong cash position provide a modest cushion.
Fundamentally, the company posted flat revenue (-0.8% YoY) with a negative profit margin (-3.6%) and a negative ROE, while its forward earnings estimate (+$12.19 EPS) and a forward PE of 13.5 are well below the industry average of 25.5, hinting at a value tilt. Recent guidance cuts tied to $200 M of divestitures and a neutral analyst rating add downside pressure, but strategic collaborations and a strong cash position provide a modest cushion.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price modestly below short‑term SMA20 but above fair value
- Bullish MACD histogram with neutral RSI
- Decreasing volume and high short‑term volatility
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Guidance reduction due to $200 M divestitures
- Negative profit margin and ROE offset by low forward PE
- Strategic collaborations that may improve margins
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- Current price ~55% above DCF fair value
- Sustained revenue decline and negative earnings history
- High beta (1.5) and elevated volatility increasing downside risk
Key Metrics & Analysis
Financial Health
Revenue Growth-0.80%
Profit Margin-3.60%
P/E Ratio13.5
ROE-4.23%
ROA4.24%
Debt/Equity81.95
P/B Ratio2.6
Op. Cash Flow$737.6M
Free Cash Flow$572.4M
Industry P/E25.5
Technical Analysis
TrendNeutral
RSI48.1
Support$149.64
Resistance$182.65
MA 20$165.36
MA 50$182.01
MA 200$173.42
MACDBullish
VolumeDecreasing
Fear & Greed Index72.43
Valuation
Fair Value$107.44
Target Price$199.07
Upside/Downside20.55%
GradeOvervalued
TypeValue
Risk Assessment
Beta1.53
Volatility50.51%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.